rifaximin - Profile

What are the generic drug sources for rifaximin and what is the scope of freedom to operate?

Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Rifaximin has one hundred and twenty-three patent family members in thirty-one countries.

There are six tentative approvals for this compound.

Summary for rifaximin

International Patents:	123
US Patents:	20
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rifaximin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for rifaximin

Constraining patent/regulatory exclusivity:

8,193,196

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

8,193,196

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for RIFAXIMIN

Applicant	Application No.	Strength	Dosage Form
		550MG	TABLET;ORAL
		550MG	TABLET;ORAL
		200MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for RIFAXIMIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIFAXAN	Tablets	rifaximin	200 mg	021361	1	2019-01-28
XIFAXAN	Tablets	rifaximin	550 mg	021361	1	2015-12-18

US Patents and Regulatory Information for rifaximin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	7,928,115
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	10,703,763
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	8,741,904		Y	Y

Expired US Patents for rifaximin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004	8,518,949
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	7,906,542
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	9,271,968

International Patents for rifaximin

Country	Patent Number	Title	Estimated Expiration
China	102625701
China	102596250
Montenegro	P34408	NOVI POLIMORFNI OBLICI RIFAKSIMINA, POSTUPAK NJIHOVE PROIZVODNJE I NJIHOVA UPOTREBA U MEDICINSKIM PREPARATIMA (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)

Rifaximin Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

What Defines Rifaximin’s Market Position?

Rifaximin is an antibiotic targeting gastrointestinal infections, primarily used for conditions such as hepatic encephalopathy, irritable bowel syndrome with diarrhea (IBS-D), and travelers’ diarrhea. It is marketed under the brand name Xifaxan by AbbVie, with additional formulations licensed by other firms.

Key points:

• Rifaximin's mechanism involves broad-spectrum activity against Gram-positive and Gram-negative bacteria.
• It exhibits low systemic absorption, reducing systemic side effects.
• FDA approval since 2004 for hepatic encephalopathy and IBS-D.
• Market exclusivity could expire in various regions between 2024-2030, depending on patent status and patent extensions.

What Are the Market Dynamics and Growth Drivers?

Parameter	Data/Insights
Current Market Size	Estimated at $2.2 billion globally in 2022.[1]
Compound Annual Growth Rate (CAGR)	Projected at about 7% from 2023 to 2030.[2]
Regional Trends	North America dominates the market (~80%), driven by high prevalence of liver and GI conditions. Asia-Pacific shows growth potential due to rising healthcare infrastructure.
Off-label Use	Limited data, but some off-label applications include Clostridium difficile infections.

Growth is underpinned by:

• Increasing prevalence of hepatic diseases.
• Aging populations.
• Rising willingness to treat IBS-D proactively.
• Patent expiry risks, prompting patent filings and formulations.

How Do Revenue Streams Breakdown?

Segment	Details
Prescription Drugs	Main revenue driver, with Xifaxan’s US sales accounting for roughly 70% of total revenues.[3]
Regional Distributors	Significant in emerging markets.
Licensing	Licenses granted for formulations in specific markets; royalties can represent a secondary revenue source.

What Patent and Regulatory Landscape Challenges Exist?

• Patent protection broadly extends until 2024-2030.[4]
• Patent cliff risk prompts companies to explore drug line extensions or new formulations.
• Regulatory hurdles vary by country; FDA approval is granted, but EMA and other agencies may have differing standards.
• Market exclusivity: US patents may be challenged unless extended via formulations or new indications.

How Do Competitive Dynamics and Pipeline Developments Influence Investment?

Competition

• Limited direct competitors in the same niche, but other antibiotics may target overlapping infections.
• Generic versions could enter post-patent expiry, impacting revenue.

Pipeline

• Pipeline drugs include rifamycin derivatives with broader spectra or improved delivery.
• Clinical trials exploring additional indications like inflammatory bowel disease (IBD) are ongoing.
• The presence of pipeline candidates indicates potential future revenue streams or threats.

Innovation prospects

• Microbiome modulation therapies could diminish traditional antibiotic use.
• New formulations (e.g., extended-release) may extend patent protections or create new market segments.

How Do Financials and Valuations Look?

Indicator	Data/Estimate
Revenue (2022)	Approx. $350 million for Xifaxan (AbbVie's global sales).[3]
Operating Margin	Historically above 30%, but influenced by R&D investments and patent litigation costs.
Valuation Approaches	Discounted cash flow (DCF) models, comparable company analysis (CCA) with biotech and pharma peers.
Price/Earnings Ratio	Usually high owing to growth prospects; needs comparison with biotech averages (~20-25).[5]

Investment Risks and Opportunities

Risks:

• Patent expiry leading to generic competition.
• Off-label regulatory actions limiting scope.
• Clinical trial failures of pipeline candidates.
• Potential for resistance development.

Opportunities:

• Expanding indications such as IBD.
• Geographic expansion in emerging economies.
• Patent extensions via formulation innovation.

Key Takeaways

• Rifaximin remains a niche but growing antibiotic with a strong market position driven by GI and hepatic disease prevalence.
• Patent expiration risks heighten the importance of pipeline development and formulation innovation.
• The valuation is supported by established revenues, but competitive threats post-patent expiration create downside risk.
• Entry into new indications or markets could positively influence long-term outlooks.
• Monitoring patent status, pipeline progress, and regulatory changes is essential for investment decisions.

FAQs

1. What is the primary revenue driver for rifaximin?
AbbVie's Xifaxan accounts for the majority of revenue, generated mainly in North America.

2. How long does patent protection for rifaximin typically last?
Patent protection extends until 2024-2030, varying by jurisdiction and patent extensions.

3. Are there significant competitors to rifaximin?
No direct alternatives in all indications, but generic versions upon patent expiry pose challenges.

4. What pipeline developments could impact rifaximin’s future?
New formulations, extended indications like IBD, and combination therapies are under investigation.

5. What are the main risks associated with investing in rifaximin?
Patent expiration, competing generics, clinical failure of pipeline drugs, and regulatory restrictions.

---

References

[1] MarketsandMarkets. (2022). Antibiotics Market Size, Share & Trends.
[2] Grand View Research. (2023). Gastrointestinal Drugs Market Forecast.
[3] AbbVie Earnings Reports. (2022).
[4] PatentScope. WIPO. (2022). Rifaximin patent filings and expiry dates.
[5] Bloomberg. (2023). Pharma industry valuation multiples.